Price Change to Note: What’s Propelling Curis, Inc. to Increase So Much?

Price Change to Note: What's Propelling Curis, Inc. to Increase So Much?

The stock of Curis, Inc. (NASDAQ:CRIS) is a huge mover today! About 267,146 shares traded hands. Curis, Inc. (NASDAQ:CRIS) has risen 82.78% since March 15, 2016 and is uptrending. It has outperformed by 77.30% the S&P500.
The move comes after 9 months positive chart setup for the $375.94 million company. It was reported on Oct, 18 by We have $4.73 PT which if reached, will make NASDAQ:CRIS worth $251.88M more.

Analysts await Curis, Inc. (NASDAQ:CRIS) to report earnings on November, 14. They expect $-0.11 EPS, down 175.00% or $0.07 from last year’s $-0.04 per share. After $-0.09 actual EPS reported by Curis, Inc. for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Out of 4 analysts covering Curis (NASDAQ:CRIS), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Sell” rating given on Monday, September 21 by Zacks. The company was maintained on Monday, November 9 by Roth Capital. The rating was initiated by FBR Capital with “Outperform” on Tuesday, August 11. The firm has “Hold” rating given on Tuesday, September 1 by Zacks. The stock of Curis, Inc. (NASDAQ:CRIS) has “Buy” rating given on Monday, November 9 by TH Capital.

According to Zacks Investment Research, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.”

Insitutional Activity: The institutional sentiment increased to 1.78 in Q2 2016. Its up 0.88, from 0.9 in 2016Q1. The ratio is positive, as 8 funds sold all Curis, Inc. shares owned while 15 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 67.45 million shares or 4.41% less from 70.56 million shares in 2016Q1.
Meridian Inv Counsel has 10,000 shares for 0.01% of their US portfolio. Susquehanna Intll Gru Ltd Liability Partnership accumulated 25,154 shares or 0% of the stock. Barclays Public Limited Liability Com holds 0% or 64,059 shares in its portfolio. Moreover, Cornerstone Cap Mngmt Ltd Liability Com has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 24,100 shares. Kcg Holding accumulated 39,817 shares or 0% of the stock. Art Ltd Liability has 30,957 shares for 0% of their US portfolio. Schwab Charles Management holds 0% or 158,654 shares in its portfolio. Teachers Advsrs, a New York-based fund reported 180,776 shares. Royal State Bank Of Canada accumulated 811,129 shares or 0% of the stock. Focused Wealth Management has 188,350 shares for 0.14% of their US portfolio. Principal Financial Group Inc Inc Inc owns 18,817 shares or 0% of their US portfolio. Legal General Public Limited Com holds 0% or 15,400 shares in its portfolio. Deutsche Financial Bank Ag owns 512,974 shares or 0% of their US portfolio. Janney Montgomery Scott Lc, a Pennsylvania-based fund reported 169,400 shares. The Maryland-based Proshare Ltd Com has invested 0% in Curis, Inc. (NASDAQ:CRIS).

Insider Transactions: Since May 26, 2016, the stock had 0 insider purchases, and 2 selling transactions for $51,750 net activity. Shares for $25,350 were sold by GREENACRE MARTYN D. 15,000 Curis, Inc. (NASDAQ:CRIS) shares with value of $26,400 were sold by KAITIN KENNETH I.

CRIS Company Profile

Curis, Inc., incorporated on February 14, 2000, is a biotechnology company. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment